These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27652261)

  • 1. Immediate Adverse Reactions to Gadolinium-Based MR Contrast Media: A Retrospective Analysis on 10,608 Examinations.
    Granata V; Cascella M; Fusco R; dell'Aprovitola N; Catalano O; Filice S; Schiavone V; Izzo F; Cuomo A; Petrillo A
    Biomed Res Int; 2016; 2016():3918292. PubMed ID: 27652261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system.
    Oudkerk M; Sijens PE; Van Beek EJ; Kuijpers TJ
    Invest Radiol; 1995 Feb; 30(2):75-8. PubMed ID: 7782190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
    Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
    Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
    Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
    Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and severity of acute adverse reactions to four different gadolinium-based MR contrast agents.
    Okigawa T; Utsunomiya D; Tajiri S; Okumura S; Sasao A; Wada H; Oda S; Arimura H; Hayashida E; Urata J; Yamashita Y
    Magn Reson Med Sci; 2014; 13(1):1-6. PubMed ID: 24492735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gadolinium released by the linear gadolinium-based contrast-agent Gd-DTPA decreases the activity of human epithelial Na
    Knoepp F; Bettmer J; Fronius M
    Biochim Biophys Acta Biomembr; 2017 May; 1859(5):1040-1048. PubMed ID: 28257815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
    Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
    Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of acute kidney injury after exposure to gadolinium-based contrast in patients with renal impairment.
    Chien CC; Wang HY; Wang JJ; Kan WC; Chien TW; Lin CY; Su SB
    Ren Fail; 2011; 33(8):758-64. PubMed ID: 21777176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse reactions to gadolinium contrast media: a review of 36 cases.
    Murphy KJ; Brunberg JA; Cohan RH
    AJR Am J Roentgenol; 1996 Oct; 167(4):847-9. PubMed ID: 8819369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute adverse reactions to magnetic resonance contrast media--gadolinium chelates.
    Li A; Wong CS; Wong MK; Lee CM; Au Yeung MC
    Br J Radiol; 2006 May; 79(941):368-71. PubMed ID: 16632615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan.
    Ishiguchi T; Takahashi S
    Drugs R D; 2010; 10(3):133-45. PubMed ID: 20945944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients from the EuroCMR Registry.
    Bruder O; Schneider S; Nothnagel D; Pilz G; Lombardi M; Sinha A; Wagner A; Dill T; Frank H; van Rossum A; Schwitter J; Nagel E; Senges J; Sabin G; Sechtem U; Mahrholdt H
    JACC Cardiovasc Imaging; 2011 Nov; 4(11):1171-6. PubMed ID: 22093267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Speciation analysis of gadolinium-based MRI contrast agents in blood plasma by hydrophilic interaction chromatography/electrospray mass spectrometry.
    Künnemeyer J; Terborg L; Nowak S; Scheffer A; Telgmann L; Tokmak F; Günsel A; Wiesmüller G; Reichelt S; Karst U
    Anal Chem; 2008 Nov; 80(21):8163-70. PubMed ID: 18821778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate hypersensitivity reaction to gadolinium-based MR contrast media.
    Jung JW; Kang HR; Kim MH; Lee W; Min KU; Han MH; Cho SH
    Radiology; 2012 Aug; 264(2):414-22. PubMed ID: 22550309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Speciation of gadolinium in surface water samples and plants by hydrophilic interaction chromatography hyphenated with inductively coupled plasma mass spectrometry.
    Lindner U; Lingott J; Richter S; Jakubowski N; Panne U
    Anal Bioanal Chem; 2013 Feb; 405(6):1865-73. PubMed ID: 23296304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections.
    Abujudeh HH; Kosaraju VK; Kaewlai R
    AJR Am J Roentgenol; 2010 Feb; 194(2):430-4. PubMed ID: 20093606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.
    Semelka RC; Hernandes Mde A; Stallings CG; Castillo M
    Magn Reson Imaging; 2013 Jan; 31(1):96-101. PubMed ID: 22898688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections.
    Aran S; Shaqdan KW; Abujudeh HH
    Clin Radiol; 2015 May; 70(5):466-75. PubMed ID: 25626627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.